Amy L. Cummings, MD

Amy L. Cummings, MD, PhD, discusses key findings from the phase 3 ADAURA trial in patients with non–small cell lung cancer harboring EGFR mutations.

Amy L. Cummings, MD, discusses the significance of the phase 3 FLAURA trial evaluating osimertinib in locally advanced or metastatic non–small cell lung cancer (NSCLC).

Although advances in metastatic non–small cell lung cancer treatment have dramatically impacted cancer mortality, the translation of these approaches to earlier-stage NSCLC has just begun to bear fruit.